German vaccine developer BioNTech posts Q1 revenues of 6.4 bln euros
BERLIN, May 9 (Xinhua) -- Revenues of German vaccine developer BioNTech in the first quarter (Q1) of 2022 more than tripled year-on-year to 6.4 billion euros (6.7 billion U.S. dollars), the company said on Monday.
The increase was "mainly due to increased commercial revenues from the supply and sales of the company's COVID-19 vaccine worldwide," BioNTech said in a statement. Net profit rose to 3.7 billion euros in Q1, compared to 1.13 billion euros in the same period last year.